TELA Bio, Inc. (TELA)
About TELA Bio, Inc.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $80.3M
- Net income
- -$38.8M
- Total assets
- $81.4M
- Market cap
- $39.4M
- Gross margin
- 67.7%
- Operating margin
- -42.0%
- Net margin
- -48.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $80.3M
- Cost of revenue
- $25.9M
- Gross profit
- $54.3M
- Operating expenses
- $88.1M
- Operating income
- -$33.8M
- Income tax
- $230.0K
- Net income
- -$38.8M
- EPS (basic)
- $-0.83
- EPS (diluted)
- $-0.83
Balance sheet
- Total assets
- $81.4M
- Current assets
- $75.6M
- Total liabilities
- $75.1M
- Current liabilities
- $18.0M
- Shareholders’ equity
- $6.3M
Cash flow
- Operating cash flow
- -$28.2M
- Investing cash flow
- $846.0K
- Financing cash flow
- $25.8M
- Net cash flow
- -$1.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $39.4M
- EPS (diluted)
- $-0.83
- Shares outstanding
- 57.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 8, 2019
TELA Bio, Inc. (TELA) Stock Price
- Reported a net loss of $38.8M in FY2025.
- Revenue grew 172% from FY2021 to FY2025.
- Gross margin of 67.7%, net margin -48.4%.
- Trading 68% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TELA Bio, Inc..
Write a review
News about TELA Bio, Inc.
News & sentiment via Polygon.io
TELA Bio, Inc.: frequently asked questions
Is TELA Bio, Inc. an American company?
TELA Bio, Inc. is a US-based company headquartered in Malvern, Pennsylvania, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is TELA Bio, Inc. headquartered?
TELA Bio, Inc. is headquartered in Malvern, Pennsylvania, United States.
Is TELA Bio, Inc. publicly traded?
Yes — TELA Bio, Inc. is a publicly traded company. Its stock trades under the ticker symbol TELA on the NASDAQ.
What does TELA Bio, Inc. do?
TELA Bio, Inc. is an American Medical Devices company in the Health & Beauty sector.
